Focused On-demand Library for Growth/differentiation factor 8

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

O14793

UPID:

GDF8_HUMAN

Alternative names:

Myostatin

Alternative UPACC:

O14793; A1C2J7; A1C2K0; Q6B0H2

Background:

Growth/differentiation factor 8, commonly known as Myostatin, plays a pivotal role in skeletal muscle physiology. This protein acts as a negative regulator, ensuring that muscle growth does not exceed physiological needs. The presence of Myostatin in the body's system is crucial for maintaining muscle size and function, highlighting its significance in muscle development and maintenance.

Therapeutic significance:

Muscle hypertrophy, a condition marked by increased muscle bulk and strength, is directly associated with variants affecting the Myostatin gene. This link underscores the protein's potential as a target for therapeutic interventions aimed at treating muscle-related disorders. By modulating Myostatin activity, it may be possible to develop treatments that enhance muscle growth in conditions where muscle strength and bulk are compromised.